Stock 1093 CSPC PHARMACEUTICAL GROUP LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages CSPC Pharmaceutical Group Ltd.

Equities

1093

HK1093012172

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:17 2024-05-07 am EDT 		5-day change 1st Jan Change
6.66 HKD -1.77% Intraday chart for CSPC Pharmaceutical Group Ltd. +2.78% -8.26%
Apr. 26 CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023 CI
Apr. 26 CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor Obtains Clinical Trial Approval in the U.S CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor Obtains Clinical Trial Approval in the U.S
CSPC Pharmaceutical's EBT Buys 8.5 Million Shares
CSPC Pharmaceutical Group Limited and CSPC Holdings Company Limited Enter into Master Sales Agreement
China's drugmakers can't sell mRNA shots but haven't quit yet
CSPC Pharmaceutical Group Limited commences an Equity Buyback Plan for 1,190,321,973 shares, representing 10% of its issued share capital, under the authorization approved on May 31, 2023.
CSPC Pharma Secures Chinese Nod for Weight Managment Drug Trials
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration
CSPC Pharmaceutical’ Blood Sugar Drug Gets Registration Approval from Chinese Regulator
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval
CSPC Pharmaceutical's Cancer Drug Gets China Nod for Clinical Trials
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024
CSPC Pharmaceutical's Profit Falls 4% on Lower Revenue, Misses Estimates
CSPC Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CSPC Pharma Obtains Clinical Trial Approval in China for Anti-Tumor Drug
CSPC Pharmaceutical Group Limited Announces Highly Selective MAT2A Inhibitor Obtains Clinical Trial Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China
CSPC Pharmaceutical Obtains New Indication Nod for Mingfule Injection
CSPC Baike's 2023 Profit Reaches 859 Million Yuan
CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1093 Stock
  4. News CSPC Pharmaceutical Group Ltd.
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW